November 12, 2021 - InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of CancerRead more
August 2, 2021 - InterVenn and SoftBank Group have officially joined forces in the company's continuing efforts in glycoproteomics research, aimed at improving therapy outcomes for cancer patients. In addition to SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management are participating as new investors in the company. InterVenn thanks everyone for sharing our vision that no one should be blindsided by disease!Read more
June 10, 2021 - InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test.Read more
InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of AdvisorsRead more
November 11, 2021 - InterVenn Biosciences today announced that company management will participate at the following virtual investor conferences
A live webcast of the Stifel event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ and will be available for 90 days thereafter.
August 2, 2021 - InterVenn Biosciences today announced that it will be participating via webcast in the Morgan Stanley 19th Annual Global Healthcare Conference. Aldo Carrascoso, CEO is scheduled to participate in a fireside chat on Friday, September 10th, 2021 at 11:45 a.m. ET.
Morgan Stanley Conference Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1488929&tp_key=346b333d38